Search / Trial NCT06616883

Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers

Launched by DONG-A ST CO., LTD. · Sep 25, 2024

Trial Information

Current as of October 07, 2024

Not yet recruiting

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Healthy volunteers
  • * BMI between 18 and 30 kg/m2
  • * Body weight: Male≥50kg, Female≥45kg
  • * Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
  • Exclusion Criteria:
  • * Subjects with clinically significant medical history
  • * Subjects with history of drug abuse or addicted

About Dong A St Co., Ltd.

Dong-A ST Co., Ltd. is a leading pharmaceutical and biotechnology company based in South Korea, dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a robust portfolio spanning various therapeutic areas, including neurology, oncology, and cardiovascular health, Dong-A ST is committed to advancing healthcare through cutting-edge clinical research and high-quality products. The company emphasizes a patient-centered approach, collaborating with global partners to enhance treatment options and improve health outcomes worldwide. Through its rigorous clinical trials and commitment to scientific excellence, Dong-A ST strives to contribute meaningfully to the global medical community.

Locations

Seoul, , Korea, Republic Of

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0